Vertex Pharmaceuticals Inc
NASDAQ: VRTX
$450.97
+$0.60 (+0.1%)
Closing Price on November 22, 2024
VRTX Articles
FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in 2016 or 2017.
Published:
Last Updated:
Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.
Published:
Last Updated:
Monday's top analyst calls include Chipotle Mexican Grill, Cisco Systems, Micron Technology, Seagate Technology, VertexPharmaceuticals, Walt Disney and Xerox.
Published:
Last Updated:
24/7 Wall St. has collected three big FDA decisions coming up in February and added some color, along with the trading range and price target.
Published:
Last Updated:
Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
Published:
Last Updated:
Friday’s top analyst upgrades, downgrades and initiations include AIG, Facebook, Gilead Sciences, Google, Regeneron Pharmaceuticals, Twitter, Valeant Pharmaceuticals and Vertex Pharmaceuticals.
Published:
Argus has been waiting for a better valuation to upgrade Vertex Pharmaceuticals, and the recent weakness in the stock price has given the firm the opportunity.
Published:
Monday's top analyst upgrades, downgrades and initiations include Atmel, BlackBerry, Citigroup, DSW, JC Penney, 2U, TD Ameritrade and Vertex Pharmaceuticals.
Published:
Tuesday's top analyst upgrades, downgrades and initiations include Apple, DuPont, Frontier Communications, Hewlett-Packard, HSBC, 3M and Red Hat.
Published:
Monday's top analyst upgrades, downgrades and initiations include AeroVironment, Gold Fields, Marvell Technology, Nokia and Silver Wheaton.
Published:
In a new research report, Cowen's well-respected analyst Ken Cacciatore makes a very good case that some huge, high-profile biotech companies could be targeted for buyouts.
Published:
S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.
Published:
A new research note from SunTrust Robinson Humphrey mentions four stocks that they think could possibly get swept up in the biotech M&A excitement.
Published:
Friday's top analyst upgrades, downgrades and initiations include Apple, Citrix Systems, Kythera Biopharmaceuticals, Mylan, Netflix and Weatherford International.
Published:
In a new report from RBC, while they think the selling and profit taking in biotechs could go on, they also hold fast that industry fundamentals are still very positive.
Published: